Patents Examined by Eric Olson
  • Methods of protecting an organ using tetrahydrocurcumin and phosphatidylcholine
    Patent number: 10781158
    Abstract: Pharmaceutical formulations of tetrahydrocurcumin and liposomes are described herein. The liposomes may comprise at least a first lipid, wherein the first lipid is a phospholipid or polyenylphosphatidylcholine are also disclosed.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: September 22, 2020
    Assignee: Bhupinder Singh
    Inventor: Bhupinder Singh
  • Sulfoalkyl ether cyclodextrin compositions
    Patent number: 10780177
    Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: September 22, 2020
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventor: Vincent D. Antle
  • Targeting fungi in combination with cancer therapy
    Patent number: 10772903
    Abstract: Described herein are methods for the treatment of cancer by modulating fungal populations to enhance the therapeutic response to a cancer therapy. In particular, the present invention discloses modulating the fungal microbiome in combination with a cancer therapy to enhance the anti-tumor effect.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: September 15, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Stephen Shiao, David Underhill
  • Modified carbohydrates, compositions comprising the same, and methods of making and using the same
    Patent number: 10766970
    Abstract: Modified alginates are described herein along with hydrogels comprising the same. A modified alginate may be prepared by reacting alginate and an aromatic compound (e.g., an aromatic amine) and/or pH sensitive compound. The modified alginates, hydrogels, and/or methods described herein may be used to coat and/or encapsulate at least a portion of a bioactive substance, optionally for oral delivery in humans and other animals.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: September 8, 2020
    Assignees: Wake Forest University Health Sciences, Wake Forest University
    Inventors: Mark E. Welker, Emmanuel C. Opara, Surya R. Banks, Amber N. Weissenfluh
  • Regioselective silyl exchange of per-silylated oligosaccharides
    Patent number: 10759823
    Abstract: The present invention provides novel, regioselectively-acylated oligosaccharide compounds and methods for preparing them. In another aspect, the invention provides a method for preparing a selectively-acylated oligosaccharide. The method includes forming a reaction mixture containing a protected oligosaccharide and an acylating agent. The protected oligosaccharide includes at least three hydroxyl moieties and each hydroxyl moiety is protected with a silyl protecting group. The reaction mixture is formed under conditions sufficient to selectively replace at least one silyl protecting group with a —C(0)-C1_6 alkyl group, and the selectively-acylated oligosaccharide comprises at least one —C(0)-C1_6 alkyl group and at least one silyl protecting group.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 1, 2020
    Assignee: The Regents of the University of California
    Inventors: Jacquelyn Gervay-Hague, Matthew Schombs
  • Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by C-section
    Patent number: 10758555
    Abstract: The present invention relates to a composition comprising at least one fucosylated oligosaccharide, for use in preventing allergies and/or treating allergies and/or reducing the occurrence or the risk of allergies in an infant or a young child born from a mother deficient in at least one fucosylated oligosaccharide(s) or fed with a mother's milk deficient in at least one fucosylated oligosaccharide(s). The use of said composition in infant formula, milk fortifier or children's food is foreseen.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: September 1, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Dominique Brassart, Clemens Kunz, Norbert Sprenger
  • Compositions and methods for treating an aggregation disease or disorder
    Patent number: 10751353
    Abstract: The present invention alleviates a sign or symptom of an aggregation disease or disorder by administering an aqueous formulation comprising trehalose.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: August 25, 2020
    Assignee: Seelos Therapeutics, Inc.
    Inventor: Dalia Megiddo
  • Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
    Patent number: 10744154
    Abstract: Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-?1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: August 18, 2020
    Assignee: Galectin Therapeutics, Inc.
    Inventors: David Platt, Eliezer Zomer, Anatole Klyosov
  • Pest control composition including novel iminopyridine derivative
    Patent number: 10736319
    Abstract: Provided is a pest control composition containing a novel iminopyridine derivative and other pest control agents. Provided is a pest control composition containing an iminopyridine derivative represented by the following Formula (I) and at least one of other pest control agents: [in the formula (I), Ar represents a 5- to 6-membered heterocycle which may be substituted, A represents a heterocycle having a 5- to 10-membered unsaturated bond including one or more nitrogen atoms, and has an imino group substituted with an R group at a position adjacent to the nitrogen atom present on the cycle, Y represents hydrogen, halogen and the like, and R represents any one of groups represented by the following Formulae (a) to (e), (y) or (z)].
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: August 11, 2020
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Ryo Horikoshi, Yasumichi Onozaki, Satoshi Nakamura, Masahiro Nomura, Makoto Matsumura, Masaaki Mitomi
  • Polymorphic forms of sofosbuvir
    Patent number: 10738071
    Abstract: The present disclosure provides novel crystalline sofosbuvir form-M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage forms.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: August 11, 2020
    Assignee: Mylan Laboratories Limited
    Inventors: Ramakoteswara Rao Jetti, Hemant Malhari Mande, Anjaneyaraju Indukuri, Narasimha Murty Pilli, Ravi Venkata Naga Vikas Chandra Dev, Vijaya Krishna Ravi
  • Process of preparing an esterified cellulose ether in the presence of an alkali metal carboxylate and an aliphatic carboxylic acid
    Patent number: 10730957
    Abstract: In a process for preparing an esterified cellulose ether a cellulose ether is esterified with (i) an aliphatic monocarboxylic acid anhydride or (ii) a dicarboxylic acid anhydride or (iii) a combination of an aliphatic monocarboxylic acid anhydride and a dicarboxylic acid anhydride in the presence of an alkali metal carboxylate and an aliphatic carboxylic acid, wherein the molar ratio [alkali metal carboxylate/anhydroglucose units of cellulose ether] is not more than [1.20/1] and the molar ratio [aliphatic carboxylic acid/anhydroglucose units of cellulose ether] is from [3.55/1] to [9.0/1].
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: August 4, 2020
    Assignee: Dow Global Technologies LLC
    Inventors: Oliver Petermann, Matthias Sprehe, Warren K. Miller
  • Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array
    Patent number: 10724143
    Abstract: There is disclosed an electrochemical deblocking solution for use on an electrode microarray. There is further disclosed a method for electrochemical synthesis on an electrode array using the electrochemical deblocking solution. The solution and method are for removing acid-labile protecting groups for synthesis of oligonucleotides, peptides, small molecules, or polymers on a microarray of electrodes while substantially improving isolation of deblocking to active electrodes. The method comprises applying a voltage or a current to at least one electrode of an array of electrodes. The array of electrodes is covered by the electrochemical deblocking solution.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: July 28, 2020
    Assignee: CustomArray, Inc.
    Inventors: Karl Maurer, John J. Cooper
  • Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children
    Patent number: 10709721
    Abstract: The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide in a particular ratio, for use in preventing and/or treating gastrointestinal infections and/or gastrointestinal inflammations in an infant or a young child.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: July 14, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Norbert Sprenger, Dominique Brassart, Delphine Egli
  • Pharmaceutical anti-infective composition for inhalation
    Patent number: 10709723
    Abstract: An anti-infective composition for inhalation, containing, at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof; and an effective amount of a biofilm modifier which is a macrolide compound or salt thereof.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: July 14, 2020
    Assignee: GALEPHAR PHARMACEUTICAL RESEARCH, INC.
    Inventors: Arthur M. Deboeck, Phillipe Baudier, Francis Vanderbist
  • Chemical compounds
    Patent number: 10710963
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 14, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
    Patent number: 10703826
    Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: July 7, 2020
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
  • Phosphotriazole MRNA 5?-end cap analogs, composition comprising the same, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule, protein or peptide
    Patent number: 10696709
    Abstract: The object of the invention is a compound of formula (I), or a stereoisomer or salt thereof, wherein R1 and R2 are selected from the group consisting of N, N+—CH3, N+—C2H5, N+—C3H8, N+—C4H5, N+—CH2C6H5 wherein at least one of R1, R2 is not N. n and m are independently chosen from the group consisting of 0, 1 and 2; X is selected from the group consisting of O, NH, S, CH2 k is 1 or 2 Y is either void or selected from the group of —CH2—, —CH2CH2—, —CH2O—, —CH2S—, —CH2NH—, —CH2CH2O—, —CH2CH2NH—, —CH2CH2S— R3, R4, R5, R6 are selected from the group consisting of H, OH, OCH3, or OCH2CH3; wherein R3 and R4 may be the same or different; R5 and R6 may be the same or different; if either of R3, R4 is different than OH than R5 and R6 are both OH; if either of R5, R6 is different than OH than R3 and R4 are both OH.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: June 30, 2020
    Assignee: UNIWERSYTET WARSZAWSKI
    Inventors: Sylwia Walczak, Joanna Kowalska, Jacek Jemielity
  • Vaccines against carbapenem-resistant
    Patent number: 10688169
    Abstract: The present invention relates to synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 that are related to carbapenem-resistant Klebsiella pneumoniae capsular polysaccharide and conjugates thereof. Said conjugates and pharmaceutical composition containing said conjugates are useful for prevention and/or treatment of diseases associated with carbapenem-resistant Klebsiella pneumoniae. Furthermore, the synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 are useful as marker in immunological assays for detection of antibodies against carbapenem-resistant Klebsiella pneumoniae bacteria.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: June 23, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Guozhi Xiao, Naeem Khan, Chakkumkal Anish
  • Treatment of metabolic disorders in equine animals
    Patent number: 10688116
    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: June 23, 2020
    Inventors: Dania Birte Reiche, Nicole Mohren, Laura Johnston, Bruce Somerville, Rebecca K. Voth
  • Combination therapies for treatment of cancer
    Patent number: 10682356
    Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: June 16, 2020
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim